NCT04729348: Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

NCT04729348
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic antibody, Tyrosine-Kinase inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Leptomeningeal Disease
Additional Notes: 
Exclusions: Patients with prior treatment targeting VEGF-directed angiogenesis, any anti-PD-1, anti-PD-L1, anti-PD-L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137)
https://ClinicalTrials.gov/show/NCT04729348

Comments are closed.

Up ↑